NCT01452607View on ClinicalTrials.gov

Study to Evaluate the Safety and Pharmacokinetics of SPI-1005

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2006

Conditions
Hearing LossCancer
Interventions
DRUG

SPI-1005

200 mg Ebselen oral capsules (SPI-1005), single dose

DRUG

Placebo

0 mg Ebselen oral capsules (SPI-1000), single dose

Trial Locations (1)

68502

MDS Pharma Services, Lincoln

All Listed Sponsors
lead

Sound Pharmaceuticals, Incorporated

INDUSTRY

NCT01452607 - Study to Evaluate the Safety and Pharmacokinetics of SPI-1005 | Biotech Hunter | Biotech Hunter